Uncategorized

AlzeCure Gets an Abstract on Phase II Clinical Data with ACD440 for Neuropathic Pain Accepted at Pain Conference

AlzeCure Pharma announced that an abstract on ACD440, the leading non-opioid drug candidate in the Painless platform, has been accepted for presentation at the annual pain conference to be held by the Swedish Pain Society in Uppsala, Sweden, on October 12-13.

AlzeCure Gets an Abstract on Phase II Clinical Data with ACD440 for Neuropathic Pain Accepted at Pain Conference Read More »

PHAXIAM Therapeutics announces the completion of its reverse share split

PHAXIAM Therapeutics, announces the completion of the reverse share split of the shares composing the Company’s share capital, as decided by the Executive Director on July 27th, 2023, following sub-delegation granted by the Board of Directors on June 23rd, 2023, made in accordance with the twenty-third extraordinary resolution of the General Shareholders’ Meeting of June

PHAXIAM Therapeutics announces the completion of its reverse share split Read More »

Scroll to Top